^
Association details:
| Biomarker: | MET exon 14 mutation + ALK wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tabrecta (capmatinib) (c-MET inhibitor) + spartalizumab (PDR001) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
994P - Efficacy and safety of capmatinib plus spartalizumab in treatment-naïve patients with advanced NSCLC harboring MET exon 14 skipping mutation
Published date:
09/05/2022
Excerpt:
This phase II study consisted of 2 parts: open-label, single-arm run-in part, where pts received cap 400 mg orally BID + sparta 400 mg...Tx-naïve aNSCLC pts with METex14 and without ALK or EGFR alterations were included….The ORR [95% CI] was 38.7% [21.8, 57.8] and DCR [95% CI] was 77.4% [58.9, 90.4]. Median DOR has not been reached. Median PFS [95% CI] is 13.3 months [9.3, NA] but data remains to mature further.
Trial ID:
